TP53 status and GATA6 amplification determine clinical outcome and chemosensitivity of unresectable pancreatic cancer: a single-center genomic profiling study

J. Yang MDFollow

Facility

NS/LIJ

Department

Division of Hematology/Oncology, Department of Medicine

Status

Fellow

Category

Clinical Science Research

Start Date

2-6-2021 12:00 AM

This document is currently not available here.

Share

COinS
 
Jun 2nd, 12:00 AM

TP53 status and GATA6 amplification determine clinical outcome and chemosensitivity of unresectable pancreatic cancer: a single-center genomic profiling study